Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
34 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Charleston Laboratories, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Charleston Laboratories, Inc. - Product Pipeline Review - 2014', provides an overview of the Charleston Laboratories, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Charleston Laboratories, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Charleston Laboratories, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Charleston Laboratories, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Charleston Laboratories, Inc.'s pipeline products Reasons to buy - Evaluate Charleston Laboratories, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Charleston Laboratories, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Charleston Laboratories, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Charleston Laboratories, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Charleston Laboratories, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Charleston Laboratories, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Charleston Laboratories, Inc. Snapshot 5 Charleston Laboratories, Inc. Overview 5 Key Information 5 Key Facts 5 Charleston Laboratories, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Charleston Laboratories, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Combination Treatment Modalities 11 Charleston Laboratories, Inc. - Pipeline Products Glance 12 Charleston Laboratories, Inc. - Late Stage Pipeline Products 12 Phase III Products/Combination Treatment Modalities 12 Charleston Laboratories, Inc. - Clinical Stage Pipeline Products 13 Phase II Products/Combination Treatment Modalities 13 Charleston Laboratories, Inc. - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 Charleston Laboratories, Inc. - Drug Profiles 15 CL-108 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 CLH-1T 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 CLBPC 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 CLFTC 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 CLH-10 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 CLH-5 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 CLHDC 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 CLHL 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 CLHMC 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 CLOXC 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 hydrocodone bitartrate + Undisclosed Drug 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Charleston Laboratories, Inc. - Pipeline Analysis 26 Charleston Laboratories, Inc. - Pipeline Products by Target 26 Charleston Laboratories, Inc. - Pipeline Products by Route of Administration 27 Charleston Laboratories, Inc. - Pipeline Products by Molecule Type 28 Charleston Laboratories, Inc. - Pipeline Products by Mechanism of Action 29 Charleston Laboratories, Inc. - Recent Pipeline Updates 30 Charleston Laboratories, Inc. - Locations And Subsidiaries 32 Head Office 32 Other Locations & Subsidiaries 32 Appendix 33 Methodology 33 Coverage 33 Secondary Research 33 Primary Research 33 Expert Panel Validation 33 Contact Us 34 Disclaimer 34
List of Tables Charleston Laboratories, Inc., Key Information 5 Charleston Laboratories, Inc., Key Facts 5 Charleston Laboratories, Inc. - Pipeline by Indication, 2014 7 Charleston Laboratories, Inc. - Pipeline by Stage of Development, 2014 9 Charleston Laboratories, Inc. - Monotherapy Products in Pipeline, 2014 10 Charleston Laboratories, Inc. - Combination Treatment Modalities in Pipeline, 2014 11 Charleston Laboratories, Inc. - Phase III, 2014 12 Charleston Laboratories, Inc. - Phase II, 2014 13 Charleston Laboratories, Inc. - Preclinical, 2014 14 Charleston Laboratories, Inc. - Pipeline by Target, 2014 26 Charleston Laboratories, Inc. - Pipeline by Route of Administration, 2014 27 Charleston Laboratories, Inc. - Pipeline by Molecule Type, 2014 28 Charleston Laboratories, Inc. - Pipeline Products by Mechanism of Action, 2014 29 Charleston Laboratories, Inc. - Recent Pipeline Updates, 2014 30 Charleston Laboratories, Inc., Other Locations 32
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.